MAP LC3β Activators

MAP LC3β activators are not direct activators of LC3β but instead manipulate cellular processes like autophagy, thereby indirectly affecting the lipidation and functionality of LC3β. These chemicals can be categorized primarily based on their target pathways. Rapamycin and Torin 1 are mTOR inhibitors that set off autophagy and thus lead to an increase in LC3β lipidation. Their mechanism involves the deactivation of mTOR, a central regulator of cell growth and autophagy, leading to autophagosome formation where LC3β is a key component. On the other hand, Chloroquine and Hydroxychloroquine prevent the fusion of autophagosomes with lysosomes, causing an accumulation of lipidated LC3β.

Another group of chemicals like 3-Methyladenine and Trehalose interact with the initiation steps of autophagy. For instance, 3-Methyladenine typically inhibits autophagy but can promote LC3β lipidation under specific cellular conditions. Trehalose, meanwhile, stimulates autophagy through an mTOR-independent pathway. There are also multi-target compounds like SP600125, a JNK inhibitor, and Verapamil, a calcium channel blocker, that are capable of inducing LC3β lipidation under specific conditions. Lastly, Metformin acts via AMPK activation, a pathway separate from mTOR, to initiate autophagy and thus lipidate LC3β. Together, these chemicals offer a range of mechanistic approaches to influencing the cellular level of lipidated LC3β, underscoring the complex regulatory networks that control this essential protein in autophagy.